<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05106699</url>
  </required_header>
  <id_info>
    <org_study_id>SPHIC-TR-PCa2021-01</org_study_id>
    <nct_id>NCT05106699</nct_id>
  </id_info>
  <brief_title>Carbon Ion Followed by Proton Radiotherapy for Prostate Cancer With Pelvic Lymph Nodes Metastases</brief_title>
  <official_title>Carbon Ion Boost Followed by Pelvic Proton Radiotherapy for Prostate Cancer With Pelvic Lymph Nodes Metastases: Prospective Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Proton and Heavy Ion Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Proton and Heavy Ion Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present of clinically pelvic lymph node positive (cN1) represent one of the most&#xD;
      important prognostic factors for recurrence and cancer-specific mortality of prostate cancer&#xD;
      patients. Approximately 12% of prostate cancer patients present with cN1 disease at the time&#xD;
      of diagnosis. Furthermore, with the advent of more sensitive advance diagnostic imaging&#xD;
      techniques, such as PSMA PET/CT, the likelihood that pelvic nodes will be found earlier and&#xD;
      more frequently.&#xD;
&#xD;
      Unfortunately, The optimal treatment for patients with cN1 still remains unclear. Androgen&#xD;
      deprivation therapy (ADT) is the cornerstone of prostate cancer with pelvic lymph node&#xD;
      metastasis. Some retrospective and database studies have shown that addition of local&#xD;
      radiotherapy (RT) to ADT improve the treatment outcome. The 2022 NCCN guideline recommend RT&#xD;
      combined with 2 to 3 years ADT in patients with initially diagnosed cN1 prostate cancer who&#xD;
      have a life expectancy greater than 5 years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 8, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biochemical relapse free survival</measure>
    <time_frame>From the start of systemic therapy, a median of 3 years</time_frame>
    <description>The prostate specific antigen less than nadir plus 2ng/ml (Phoenix definition)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>From the start of systemic therapy, a median of 3 years</time_frame>
    <description>The time from start of systemic therapy to tumor progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From the start of systemic therapy, a median of 3 years</time_frame>
    <description>The time from diagnosis to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metastasis free survival</measure>
    <time_frame>From the start of systemic therapy, a median of 3 years</time_frame>
    <description>The time from start of systemic therapy to tumor metastatsis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute toxicities</measure>
    <time_frame>Within 3 months of the start of particle therapy</time_frame>
    <description>Treatment related acute toxicity assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late toxicities</measure>
    <time_frame>3 months after the completion of particle therapy</time_frame>
    <description>Treatment related late toxicity assessed by Radiation Therapy Oncology Group (RTOG) scale</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Carbon ion followed by Proton radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients received whole pelvis and prostate region radiotherapy. The dose to metastatic LN was escalated using simultaneous integrated boost (SIB) technique.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>proton plus carbon ion radiation</intervention_name>
    <description>All patients received whole pelvis and prostate region proton irradiation of 46 GyE in 23 fractionsfollowed by localized carbon ion irradiation of 32GyE in 8 fractions to the prostate region. The dose to metastatic LN was escalated using simultaneous integrated boost (SIB) technique. The dose was 60-62.1GyE in 23 fractions as much as dose constraints. All patients will be recommened receive 2-3 years endocrine therapy.</description>
    <arm_group_label>Carbon ion followed by Proton radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven initial diagnosis of adenocarcinoma of the prostate;&#xD;
&#xD;
          -  Clinical stage T1-4 N0 M0;&#xD;
&#xD;
          -  Prostatic assessment by multiparametric (mp) MRI;&#xD;
&#xD;
          -  Pelvic lymph node was assessed by PSMA PET/CT and mpMRI;&#xD;
&#xD;
          -  No distant metastasis was proven by PSMA PET/CT;&#xD;
&#xD;
          -  Patients may received neoadjuvant hormonal therapy;&#xD;
&#xD;
          -  45≤ Age ≤85;&#xD;
&#xD;
          -  Adequate performance status (ECOG 0-1);&#xD;
&#xD;
          -  No previous pelvic radiation therapy (RT);&#xD;
&#xD;
          -  No previous prostatectomy;&#xD;
&#xD;
          -  No previous invasive cancer (within 5 years before the prostate cancer diagnosis);&#xD;
&#xD;
          -  Ability to understand character and individual consequences of the clinical trial;&#xD;
&#xD;
          -  Written informed consent;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No pathologically confirmed adenocarcinoma of the prostate;&#xD;
&#xD;
          -  Distant metastasis (M1);&#xD;
&#xD;
          -  Previous pelvic radiotherapy;&#xD;
&#xD;
          -  Previous prostatectomy;&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qing Zhang, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai Proton and Heavy Ion Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ping Li, M.D.</last_name>
    <phone>+86-021-38296666</phone>
    <email>ping.li@sphic.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Proton and Heavy Ion Center</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ping Li</last_name>
      <phone>+86-021-38296666</phone>
      <email>ping.li@sphic.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Qing Zhang</last_name>
      <email>qing.zhang@sphic.org.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 24, 2021</study_first_submitted>
  <study_first_submitted_qc>October 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2021</study_first_posted>
  <last_update_submitted>October 24, 2021</last_update_submitted>
  <last_update_submitted_qc>October 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Proton and Heavy Ion Center</investigator_affiliation>
    <investigator_full_name>Ping Li</investigator_full_name>
    <investigator_title>Associate chief physician</investigator_title>
  </responsible_party>
  <keyword>Carbon ion</keyword>
  <keyword>Proton</keyword>
  <keyword>prostate cancer</keyword>
  <keyword>pelvic lymph nodes metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Lymphatic Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

